Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $32.2252W HIGH $117.88
Volume
1.00 M
Value Traded
95.13 M
Short % Float
18.98%
-6.55%Week
-22.99%1 Month
-15.54%3 Month
-8.18%6 Month
-52.79%5 Year
-65.13%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.51 B
EPS (TTM)
-3.44
P/E Ratio
-
Ent. Value
3.62 B
Total Shares
54.65 M
Float Shares
46.51 M
Insiders
16.86%
Institutions
115.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DNTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Dianthus Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dianthus Therapeutics, Inc.
351Total events
15Upcoming
72Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationClaseprubartPresentation
Oral presentation of CAPTIVATE interim analysis in CIDP at AANEM 2026
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
◆Poster PresentationClaseprubartPresentation
Poster of CAPTIVATE interim analysis in CIDP at AANEM 2026
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
◆Poster PresentationClaseprubartPresentation
Poster on sustained safety and efficacy of claseprubart in gMG at AANEM 2026
Generalized Myasthenia Gravissource ↗
▲Development Candidate NominationDNTH312Preclinical
DNTH312 announced as new pipeline candidate
▲Interim AnalysisClaseprubartTrial
Interim Responder Analysis from Part A of CAPTIVATE
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
▲Enrollment CompleteClaseprubartTrial
Enrollment completed in MoMeNtum
Multifocal Motor Neuropathy (MMN)source ↗
▲Trial InitiationClaseprubartTrial
Initiation of Phase 3 EMERGE trial of claseprubart in gMG
generalized Myasthenia Gravissource ↗
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
●Trial InitiationClaseprubartTrial
Phase 3 EMERGE trial initiated
generalized Myasthenia Gravis (gMG)source ↗
▲Orphan Drug DesignationClaseprubartDesignation
Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis
Myasthenia Gravissource ↗
●Quarterly UpdateCorporate
Reported Q1 2026 financial results with cash position of ~$1.2 billion
▲Orphan Drug DesignationClaseprubartDesignation
FDA granted Orphan Drug Designation to claseprubart for Myasthenia Gravis
Myasthenia Gravissource ↗
●Equity OfferingCorporate
Inducement grants of stock options to six new non-executive employees
◆Interim AnalysisClaseprubartTrial
Interim responder analysis of Phase 3 CAPTIVATE trial in CIDP
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
◆Trial InitiationClaseprubartTrial
Phase 3 registrational trial of claseprubart in gMG expected to initiate
generalized Myasthenia Gravissource ↗
◆Topline ReadoutDNTH212Clinical Data
Phase 1 healthy volunteer data for DNTH212 anticipated
Healthy Volunteerssource ↗
◆Interim AnalysisClaseprubartTrial
Interim responder analysis of Phase 3 CAPTIVATE trial expected
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
◆Topline ReadoutClaseprubartClinical Data
Top-line results anticipated from Phase 2 MoMeNtum trial in MMN
Multifocal Motor Neuropathy (MMN)source ↗
▲Enrollment CompleteClaseprubartTrial
CAPTIVATE Part A early GO decision after 20 confirmed responders
chronic inflammatory demyelinating polyneuropathysource ↗
▼Equity OfferingCorporate
Closed upsized $719 million underwritten public offering including full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of upsized $625 million underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Proposed $400 million underwritten public offering of common stock and pre-funded warrants
◆Oral PresentationClaseprubartPresentation
Conference call and webcast to discuss interim responder analysis results from Part A of Phase 3 CAPTIVATE trial
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
▲Interim AnalysisClaseprubartTrial
Early GO decision based on interim responder analysis in Part A of CAPTIVATE trial
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
▲DSMB ReviewClaseprubartTrial
Independent DSMB review confirmed GO decision
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
◆Poster PresentationClaseprubartPresentation
Three poster presentations describing claseprubart Phase 2 MaGic results and in vitro data at MDA Conference
generalized Myasthenia Gravissource ↗
▼Equity OfferingCorporate
Upsized underwritten public offering raising approximately $719 million
▲Interim AnalysisClaseprubartTrial
Early GO decision reached in CAPTIVATE Part A based on 20 confirmed responders
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
▲FDA Feedback ReceivedClaseprubartFDA Meeting
FDA feedback on three proposals for claseprubart trials
◆Oral PresentationPresentation
CEO Marino Garcia to participate in fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Oral PresentationPresentation
Corporate overview presentation at 44th Annual J.P. Morgan Healthcare Conference
◆Pipeline PrioritizationDNTH212Corporate
Update on indication prioritization for DNTH212 planned
▲End Of Phase 2 MeetingClaseprubartFDA Meeting
Successful completion of end-of-Phase 2 meeting with FDA for gMG
generalized Myasthenia Gravissource ↗
▲Trial InitiationLBL-047Trial
Phase 1 study initiated in China for LBL-047
Sjögren's disease, systemic lupus erythematosus, dermatomyositissource ↗
●Trial InitiationDNTH212Trial
Phase 1 study initiated in China
Systemic Lupus Erythematosus (SLE)source ↗
▲Topline ReadoutClaseprubartClinical Data
Phase 2 MaGic trial topline results: statistically significant and clinically meaningful improvements in MG-ADL, QMG, and other efficacy measures at Week 13
generalized myasthenia gravissource ↗
▲Partnership / LicenseDNTH212Corporate
Exclusive license agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor
◆Oral PresentationClaseprubartPresentation
Topline Results from MaGic Phase 2 trial of claseprubart in gMG presented at AANEM 2025
generalized Myasthenia Gravissource ↗
▲Full ResultsClaseprubartClinical Data
New open-label extension data and post hoc analysis presented at Virtual Industry Forum
generalized Myasthenia Gravissource ↗
▲Preclinical PoCClaseprubartPreclinical
New preclinical data highlight potential efficacy benefits of upstream vs downstream complement inhibition
Past FDA Catalysts and PDUFA Decisions
How DNTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Claseprubart (DNTH103) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$682M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 18%
Small Cap(rank 119 of 658)
Percentile Rank
Dianthus Therapeutics, Inc. carries a moderate pipeline score (50/100), with $1.0B risk-adjusted pipeline value, led by MGTA-456 in Inherited Metabolic Disorders (IMD) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MGTA-456 Small moleculeCompletedNCT03406962 | Inherited Metabolic Disorders (IMD) | Phase 2 | COMPLETED | 8 | Jan 15, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every DNTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Claseprubart Orphan | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | 2026-09-29 | 75% response rate observed in the interim responder analysis of the first 40 participants completing unblinded Part ARead More | Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CARR EDWARDOfficer (CHIEF ACCOUNTING OFFICER) | Option | 20,000 20,000 held | $17.88 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DNTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 16.3 % (5.8 %) | 247.32 M | 2.54 M |
DNTH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DNTH ranks across every disease it competes in
Competitive Position is a premium feature
See how DNTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDNTH News
DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics has announced the granting of equity awards to six new non-executive employees as part of its hiring process. These inducement grants, approved by the Compensation Committee, consist of stock options to purchase 106,000 shares at an exercise price of $88.32. The options will vest over a four-year period, highlighting the company's strategy to attract and retain talent.
Read more →DNTHDianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Dianthus Therapeutics announced multiple presentations for claseprubart at the AANEM Annual Meeting in 2026. The data highlights the sustained efficacy and safety profile of claseprubart for treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The presentations include an oral presentation and several posters detailing the promising results from ongoing clinical trials.
Read more →DNTHDianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics, a clinical-stage biotechnology firm, announced its participation in three investor conferences in September 2026. CEO Marino Garcia and EVP Ryan Savitz will host one-on-one meetings and engage in fireside chats at the Wells Fargo, Citi, and Cantor conferences. This involvement highlights the company's commitment to investor relations and its focus on severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Dianthus Therapeutics reported its Q2 2026 financial results and highlighted significant advancements in its clinical pipeline, particularly with claseprubart for neuromuscular diseases. The company initiated Phase 3 trials for generalized Myasthenia Gravis and reported promising interim results from the CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy. Additionally, DNTH212 is progressing towards Phase 1 trials, with strong financial backing for future developments.
Read more →DNTHDianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Dianthus Therapeutics has announced DNTH312, a first-in-class bifunctional fusion protein designed to inhibit C1s and BAFF/APRIL pathways, targeting severe autoimmune diseases. The drug shows comparable potency to claseprubart and aims to be Phase 1 ready by the end of 2027. DNTH312 is expected to enhance clinical efficacy and expand treatment options for patients.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Dianthus Therapeutics announced the granting of equity awards to six new non-executive employees as inducement for their acceptance of employment. These grants, approved by the Compensation Committee, consist of non-qualified stock options totaling 87,000 shares, with a 10-year term and specific vesting conditions. This move aligns with Nasdaq Listing Rule 5635(c)(4).
Read more →DNTHDianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics announced the granting of equity awards to five new non-executive employees as part of their employment inducement strategy. These grants, approved by the independent Compensation Committee, include stock options for a total of 58,000 shares with a 10-year term. The initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's talent pool.
Read more →DNTHDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Dianthus Therapeutics has launched the Phase 3 EMERGE trial for claseprubart in patients with generalized Myasthenia Gravis (gMG). This global, randomized, placebo-controlled study aims to evaluate the efficacy of claseprubart, following promising Phase 2 results. Top-line data is expected in the second half of 2028, further advancing the company's neuromuscular franchise.
Read more →DNTH▲ +7.4%on this news
Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, i
Dianthus is focusing on the development of two investigational autoimmune therapies, claseprubart and DNTH212, aiming to provide convenient self-administration options for patients. The company maintains a strong financial position, with expectations of positive clinical developments and trials intended for several conditions, including chronic inflammatory demyelinating polyneuropathy and myasthenia gravis. However, risks abound as the success of these therapies heavily depends on forthcoming clinical trial results and regulatory approvals. Future milestones include scheduled data releases from various studies throughout 2026, showing potential for best-in-disease efficacy.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Dianthus Therapeutics has announced the granting of equity awards to three new non-executive employees as part of their hiring process. These inducement grants, approved by the Compensation Committee, include non-qualified stock options for a total of 60,000 shares. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →DNTH▼ -8.8%on this newsshared move
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics announced the granting of equity awards to three new non-executive employees as part of their inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants consist of stock options for 60,000 shares with a 10-year term and specific vesting conditions. This move aims to enhance the company's capabilities in developing therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics to Participate in Two Investor Conferences
Dianthus Therapeutics will participate in two investor conferences in June 2026. Ryan Savitz, the EVP, CFO, and CBO, will engage in a fireside chat at the Jefferies Global Healthcare Conference, while CEO Marino Garcia will speak at the Goldman Sachs Annual Global Healthcare Conference. These events aim to enhance investor relations and showcase the company's commitment to developing therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics reported a pivotal early GO decision in its CAPTIVATE study for claseprubart, achieving 20 confirmed responders with fewer participants than planned. The company also received Orphan Drug Designation for claseprubart in Myasthenia Gravis and is on track to initiate a Phase 3 trial in mid-2026. Additionally, Dianthus is building a rheumatology franchise around its drug DNTH212, targeting Sjögren’s Disease, Systemic Lupus Erythematosus, and Dermatomyositis.
Read more →DNTHLBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics has prioritized LBL-047 for clinical development in Sjögren's disease, systemic lupus erythematosus, and dermatomyositis. This bifunctional fusion protein aims to address autoimmune diseases by targeting both innate and adaptive immune systems. A Phase 1 study has begun, with results expected in the second half of 2026. The recent public offering provides significant funding for its development.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Dianthus Therapeutics has announced the granting of equity awards to six new non-executive employees as part of their inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants include stock options for a total of 135,000 shares, with specific vesting terms. This move is aimed at enhancing the company's workforce as it develops therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 6, 2026
Dianthus Therapeutics announced the granting of equity awards to eight new non-executive employees as part of its recruitment strategy. These inducement grants, approved by the independent Compensation Committee, include stock options for a total of 135,000 shares. The options are designed to vest over four years, supporting the company's goal of developing therapies for severe autoimmune diseases.
Read more →About Dianthus Therapeutics, Inc.
Headquarters7 TIMES SQUARE, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next DNTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime